XM does not provide services to residents of the United States of America.

F
F

Fiserv

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 months ago

Payments company Adyen's shares plummet by a third after earnings miss

UPDATE 7-Payments company Adyen's shares plummet by a third after earnings miss Adyen earnings miss on both sales growth and margins Share fall reflects worries on company and sector Company cites US competition, hiring costs Adyen stands by medium-term financial forecasts Adds CEO comment in paragraphs 4-6, updates shares in paragraphs 1 and 8. By Toby Sterling and Elizabeth Howcroft AMSTERDAM, Aug 17 (Reuters) - Dutch payments processor Adyen NV's ADYEN.AS shares fell by a third on Thursday, w
F
M
N
P
S
Reuters - 2 months ago

PayPal would slot well in a different wallet

BREAKINGVIEWS-PayPal would slot well in a different wallet The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Lauren Silva Laughlin NEW YORK, Aug 15 (Reuters Breakingviews) - After 25 years of muscling in on mega-finance, PayPal PYPL.O should benefit from outside help. A six-month CEO search led to Alex Chriss at Intuit INTU.O to replace retiring Dan Schulman .
C
E
F
I
J
P
V
Reuters - 2 months ago

U.S. STOCKS Boeing, Warrantee, Fiserv

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Warrantee, Fiserv Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's top indexes were set for a lower open on Wednesday as investors assessed mixed earnings from Microsoft and Alphabet ahead of a Federal Reserve rate hike that could push borrowing costs to their highest since the global financial crisis.
A
A
A
B
B
D
F
F
G
M
M
T
C
T
U
E
T
Reuters - 2 months ago

Tech splits, banks merge and Fed decides

MORNING BID AMERICAS-Tech splits, banks merge and Fed decides A look at the day ahead in U.S. and global markets from Mike Dolan Alphabet outshone Microsoft as the latest two of the tech giants reported earnings overnight, with another regional bank merger exciting financial stocks as the Fed decides on interest rates. The blizzard of market-moving news has done little to rein in the relentless climb of Wall St stocks so far this week, with the S&P500 .SPX hitting new highs for the year and the
A
A
B
E
F
F
G
M
M
N
S
T
U
L
J
U
U
U
A
A
G
U
Reuters - 3 months ago

Companies in Alzheimer's race after US nod for Eisai/Biogen drug

FACTBOX-Companies in Alzheimer's race after US nod for Eisai/Biogen drug July 7 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.
B
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.